Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045815 | 0.96 | ADRB2 (0.34) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5140653 | 0.96 | ADRB2 (0.36) | ADRB2ADRB1ADRB3 | |
| SCHEMBL29262873 | 0.95 | ADRB2 (0.36) | ADRB2ADRB1ADRB3 | |
| SCHEMBL5049088 | 0.88 | POLB (0.31) | — | |
| SCHEMBL23483313 | 0.88 | — | — | |
| SCHEMBL9656868 | 0.88 | — | — | |
| SCHEMBL16995921 | 0.88 | — | — | |
| SCHEMBL238099 | 0.88 | — | — | |
| SCHEMBL9657891 | 0.88 | — | — | |
| SCHEMBL18316479 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | GIVAUDAN SA (CH) | 2026-03-31 | — | — | US | claimed |
| US-12559703-B2 | Fragrance composition | GIVAUDAN SA (CH) | 2026-02-24 | — | — | US | claimed |
| EP-4695016-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2026-02-18 | — | — | EP | claimed |
| EP-4655373-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2025-12-03 | — | — | EP | claimed |
| EP-4581114-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Novozymes A/S (DK) | 2025-07-09 | — | — | EP | claimed |
| US-20250163343-A1 | FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT | INTERNATIONAL FLAVORES & FRAGRANCES INC. | 2025-05-22 | — | — | US | claimed |
| CN-119698458-A | Improvements in or relating to organic compounds improvements relating to organic compounds | 诺维信公司 | 2025-03-25 | — | — | CN | claimed |
| EP-4486857-A1 | FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT | International Flavors & Fragrances Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| CN-119156438-A | Perfume composition for sleep improvement | 国际香料和香精公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2024213507-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-10-17 | — | — | WO | claimed |
| US-9125828-B2 | MOC compositions | GIVAUDAN SA (CH) | 2015-09-08 | — | — | US | claimed |
| US-20130336911-A1 | MOC Compositions | GIVAUDAN SA (CH) | 2013-12-19 | — | — | US | claimed |
| EP-2652102-A1 | MOC COMPOSITIONS | Givaudan SA (CH) | 2013-10-23 | — | — | EP | claimed |
| WO-2012080235-A1 | MOC COMPOSITIONS | GIVAUDAN SA (CH) | 2012-06-21 | — | — | WO | claimed |
| US-7390779-B2 | Cycloalkanecarboxylic acid derivatives as fragants with musk characteristics | GIVAUDAN SA (CH) | 2008-06-24 | — | — | US | claimed |
| EP-1392640-B1 | CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS FRAGRANTS WITH MUSK CHARACTERISTICS | GIVAUDAN SA (CH) | 2007-12-19 | — | — | EP | claimed |
| US-20040234568-A1 | Cycloalkanecarboxylic acid derivatives as fragants with musk characteristics | GIVAUDAN SA (CH) | 2004-11-25 | — | — | US | claimed |
| EP-1392640-A1 | CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS FRAGRANTS WITH MUSK CHARACTERISTICS | Givaudan SA (CH) | 2004-03-03 | — | — | EP | claimed |
| WO-2002096852-A1 | CYCLOALKANECARBOXYLIC ACID DERIVATIVES AS FRAGRANTS WITH MUSK CHARACTERISTICS | GIVAUDAN SA (CH) | 2002-12-05 | — | — | WO | claimed |
| EP-1262474-A1 | Cycloalkanecarboxylic acid derivatives as fragrants with musk characteristics | Givaudan SA (CH) | 2002-12-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | CUTA, EXOC1, EXOSC10 | ADRB2 4499/4885ADRB1 4437/4885ADRB3 4625/4885 |
| US-12559703-B2 | Fragrance composition | DHCR24, OPRD1, OR10J3 | ADRB2 423/4885ADRB1 466/4885ADRB3 635/4885 |
| US-20040234568-A1 | Cycloalkanecarboxylic acid derivatives as fragants with musk characteristics | FASN, ACMSD, CMPK1 | ADRB2 1350/4885ADRB1 1260/4885ADRB3 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.